Moreover, TGR5 is proved to improve colitis by modulating the integrity of intestinal barrier and immune response (Cipriani et al., 2011; Biagioli and Carino, 2017; Sorrentino et al., 2020), indicating its potential in alleviating chemotherapy-induced intestinal toxicity as an intervening target. The gene discussed is GPBAR1; the disease is colitis.